Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus.
4-1BB
CD40
PDL1
TNFSF
oncolytic virotherapy
single-domain antibody
surfactant protein D
vaccinia virus
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
06
2023
accepted:
24
10
2023
medline:
6
12
2023
pubmed:
6
12
2023
entrez:
6
12
2023
Statut:
epublish
Résumé
Arming oncolytic viruses with transgenes encoding immunomodulators improves their therapeutic efficacy by enhancing and/or sustaining the innate and adaptive anti-tumoral immune responses. We report here the isolation, selection, and vectorization of a blocking anti-human PDL1 single-domain antibody (sdAb) isolated from PDL1-immunized alpacas. Several formats of this sdAb were vectorized into the vaccinia virus (VV) and evaluated for their programmed cell death protein 1 (PD1)/PD1 ligand (PDL1) blocking activity in the culture medium of tumor cells infected
Identifiants
pubmed: 38053848
doi: 10.3389/fbioe.2023.1247802
pii: 1247802
pmc: PMC10694795
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1247802Informations de copyright
Copyright © 2023 Remy, Pintado, Dunlop, Schön, Kleinpeter, Rozanes, Fend, Brandely, Geist, Suhner, Winter, Silvestre, Huguet, Fitzgerald, Quéméneur and Marchand.
Déclaration de conflit d'intérêts
Authors CR, EP, PK, HR, LF, RB, MG, CR, DS, EW, NS, EQ, and J-BM were employed by the company Transgene SA. MD, SS, CH, and PF were employed by the company Randox Laboratories Ltd.
Références
Virol J. 2005 Mar 22;2:23
pubmed: 15784143
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34172514
Mol Cancer Ther. 2009 Oct;8(10):2861-71
pubmed: 19825804
Proc Natl Acad Sci U S A. 1985 Jan;82(1):19-23
pubmed: 3855541
Oncoimmunology. 2016 Sep 27;5(11):e1238540
pubmed: 27999756
Mol Ther. 2021 May 5;29(5):1668-1682
pubmed: 33845199
Theranostics. 2022 Jan 1;12(4):1486-1499
pubmed: 35198053
J Immunol Methods. 2007 Jul 31;324(1-2):13-25
pubmed: 17568607
J Immunol. 2008 Dec 1;181(11):7936-43
pubmed: 19017984
Cancer Res. 2017 Aug 1;77(15):4146-4157
pubmed: 28536278
J Immunol. 2009 Aug 1;183(3):1851-61
pubmed: 19596991
Mol Ther Oncolytics. 2019 Mar 27;14:1-14
pubmed: 31011628
Vaccine. 2012 Jan 17;30(4):691-702
pubmed: 22146759
Eur J Immunol. 2001 Oct;31(10):3094-100
pubmed: 11592086
MAbs. 2016;8(1):113-9
pubmed: 26496429
J Mol Biol. 2018 May 11;430(10):1495-1509
pubmed: 29626540
Cell Host Microbe. 2007 Oct 11;2(4):221-8
pubmed: 18005740
Hum Gene Ther. 2022 Mar;33(5-6):250-261
pubmed: 34731019
BioDrugs. 2023 Jan;37(1):21-33
pubmed: 36571696
J Virol. 2006 Feb;80(4):1762-72
pubmed: 16439533
Mol Immunol. 2000 Aug;37(10):579-90
pubmed: 11163394
Nat Commun. 2017 Mar 27;8:14754
pubmed: 28345650
ISRN Oncol. 2013 Jun 11;2013:371854
pubmed: 23840967
Oncoimmunology. 2016 Sep 9;5(10):e1220467
pubmed: 27853644
Int J Mol Sci. 2021 Oct 21;22(21):
pubmed: 34768776
Front Cell Dev Biol. 2021 Feb 11;8:615141
pubmed: 33644033
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35058324